使用整合酶抑制剂对比蛋白酶抑制剂与HIV病毒抑制改善相关
本研究为观察性研究,纳入2011年1月至2021年12月在城市安全网医院接受产前保健并分娩的604例HIV孕妇,比较双核苷类逆转录酶抑制剂联合整合酶链转移抑制剂或蛋白酶抑制剂者的分娩时病毒抑制情况。整合酶链转移抑制剂组病毒抑制率147/193(76%)高于蛋白酶抑制剂组275/411(67%)(比值比1.59;95%置信区间1.08-2.33)。作者认为结果支持将双核苷类逆转录酶抑制剂联合整合酶链转移抑制剂作为妊娠期一线抗逆转录病毒治疗方案。
要点
- 分娩时整合酶链转移抑制剂组病毒抑制率76%(147/193),蛋白酶抑制剂组67%(275/411)。
- 比值比1.59(95%置信区间1.08-2.33),整合酶链转移抑制剂组病毒抑制频率更高。
- 研究期间蛋白酶抑制剂使用减少,整合酶链转移抑制剂使用增加。
核心结论
- 在HIV孕妇中,分娩时双核苷类逆转录酶抑制剂联合整合酶链转移抑制剂者的病毒抑制比联合蛋白酶抑制剂者更常见。
- 作者认为结果支持将双核苷类逆转录酶抑制剂联合整合酶链转移抑制剂作为妊娠期一线抗逆转录病毒治疗方案。
研究设计与样本
- 观察性研究,纳入2011年1月至2021年12月在一家城市安全网医院接受产前保健并在妊娠20周后分娩的HIV孕妇。
- 所有HIV孕妇均转诊至集中诊所接受HIV咨询、药物管理和产前保健,抗逆转录病毒治疗按基于国家指南的方案继续或启动。
- 共604例符合纳入标准的双核苷类逆转录酶抑制剂使用者,其中分娩时411例(68%)使用蛋白酶抑制剂,193例(32%)使用整合酶链转移抑制剂。
主要发现
- 整合酶链转移抑制剂组101例(17%)在产前保健开始时已接受抗逆转录病毒治疗,蛋白酶抑制剂组169例(28%)。
- 分娩时病毒抑制(病毒载量<50拷贝/mL)在整合酶链转移抑制剂组为147/193(76%),在蛋白酶抑制剂组为275/411(67%)(比值比1.59;95%置信区间1.08-2.33)。
- 在可检测到病毒的患者中,定量病毒载量无差异。
- 研究期间蛋白酶抑制剂使用减少,而整合酶链转移抑制剂使用增加。
临床怎么用
- 作者认为结果支持将双核苷类逆转录酶抑制剂联合整合酶链转移抑制剂作为妊娠期一线抗逆转录病毒治疗方案。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Current guidelines for antiretroviral therapy in pregnancy include the use of a dual-nucleoside reverse transcriptase inhibitor with either an integrase strand transfer inhibitor or a ritonavir-boosted protease inhibitor, although there is no designation of which is the preferred option. OBJECTIVE: This study aimed to compare viral suppression at delivery among patients on dual-nucleoside reverse transcriptase inhibitors combined with either an integrase strand transfer inhibitor or a protease inhibitor. A hypothesis was made that the incidence of viral suppression is higher with the use of a dual-nucleoside reverse transcriptase inhibitor backbone combined with an integrase strand transfer inhibitor than with the use of a dual-nucleoside reverse transcriptase inhibitor backbone combined with a protease inhibitor. STUDY DESIGN: This study was an observational study of pregnant patients living with HIV who received prenatal care and delivered after 20 weeks of gestation at an urban safety net hospital. All pregnant patients with HIV were referred to a centralized clinic for HIV counseling, medication management, and prenatal care. Antiretroviral therapy was continued or initiated according to protocols based on national guidance. Among patients on a dual-nucleoside reverse transcriptase inhibitor backbone combined with integrase strand transfer inhibitor vs protease inhibitor at delivery, we compared the demographics and HIV disease characteristics, including year of diagnosis, viral load, and antiretroviral therapy class. The outcome of interest was viral suppression at delivery, defined as a viral load of <50 copies/mL. RESULTS: From January 2011 to December 2021, 604 patients on dual-nucleoside reverse transcriptase inhibitor met the inclusion criteria, including 411 patients (68%) on protease inhibitor and 193 patients (32%) on integrase strand transfer inhibitor at delivery. Demographic distribution was similar, and prenatal care was initiated at 12 weeks of gestation. Among the integrase strand transfer inhibitor group, 101 (17%) were on antiretroviral therapy at initiation of prenatal care compared with 169 (28%) in the protease inhibitor group. At delivery, the frequency of viral load suppression was higher among those on an integrase strand transfer inhibitor (147/193 [76%]) than among those on a protease inhibitor (275/411 [67%]) (odds ratio, 1.59; 95% confidence interval, 1.08-2.33). Among those with a detectable virus, quantitative viral load was not different. During the study period, the use of a protease inhibitor decreased, whereas the use of an integrase strand transfer inhibitor increased. CONCLUSION: Among pregnant patients living with HIV, viral suppression was more common among those on a dual-nucleoside reverse transcriptase inhibitor backbone combined with integrase strand transfer inhibitor than among those on a dual-nucleoside reverse transcriptase inhibitor backbone protease inhibitor at delivery. Our results support the use of dual-nucleoside reverse transcriptase inhibitor with integrase strand transfer inhibitor as a first-line antiretroviral therapy regimen in pregnancy.
引用
- Kleinmann WN, Pruszynski JE, Adhikari EH, et al. Use of integrase inhibitors vs protease inhibitors is associated with improved HIV viral suppression. Am J Obstet Gynecol MFM. 2023. PMID: 37689245. doi:10.1016/j.ajogmf.2023.101151
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。